- Home
- GNFT vs DBI Comparison
GNFT vs DBI Comparison
Compare GNFT & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- DBI
- Stock Information
- Founded
- GNFT 1999
- DBI 1991
- Country
- GNFT France
- DBI United States
- Employees
- GNFT N/A
- DBI N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- DBI Clothing/Shoe/Accessory Stores
- Sector
- GNFT Health Care
- DBI Consumer Discretionary
- Exchange
- GNFT Nasdaq
- DBI Nasdaq
- Market Cap
- GNFT 190.6M
- DBI 292.2M
- IPO Year
- GNFT 2019
- DBI 1991
- Fundamental
- Price
- GNFT $3.75
- DBI $5.52
- Analyst Decision
- GNFT Strong Buy
- DBI Hold
- Analyst Count
- GNFT 1
- DBI 2
- Target Price
- GNFT $13.00
- DBI $5.75
- AVG Volume (30 Days)
- GNFT 8.9K
- DBI 2.1M
- Earning Date
- GNFT 09-19-2024
- DBI 12-10-2024
- Dividend Yield
- GNFT N/A
- DBI 3.68%
- EPS Growth
- GNFT N/A
- DBI N/A
- EPS
- GNFT 0.47
- DBI N/A
- Revenue
- GNFT $86,225,222.00
- DBI $3,050,038,000.00
- Revenue This Year
- GNFT $155.44
- DBI N/A
- Revenue Next Year
- GNFT N/A
- DBI $2.23
- P/E Ratio
- GNFT $7.55
- DBI N/A
- Revenue Growth
- GNFT 175.45
- DBI N/A
- 52 Week Low
- GNFT $3.31
- DBI $4.36
- 52 Week High
- GNFT $6.42
- DBI $11.57
- Technical
- Relative Strength Index (RSI)
- GNFT 29.68
- DBI 46.98
- Support Level
- GNFT $3.63
- DBI $5.18
- Resistance Level
- GNFT $3.94
- DBI $6.21
- Average True Range (ATR)
- GNFT 0.12
- DBI 0.43
- MACD
- GNFT 0.03
- DBI -0.05
- Stochastic Oscillator
- GNFT 0.69
- DBI 42.47
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.